Viyash Scientific Ltd

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the allotment of 6,12,773 equity shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026. The shares were allotted at exercise prices of Rs. 86 and Rs. 101 per equity share respectively. The issued and paid-up equity share capital of the Company has increased from Rs. 87,98,15,176 to Rs. 88,10,40,722.

Viyash Scientific Ltd

Viyash Scientific Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the sale of 2,47,61,691 equity shares and 2,56,04,156 equity shares by CA Harbor Investments and CA Hull Investments respectively.

Viyash Scientific Ltd

Viyash Scientific Ltd announced its Q1 FY 2026-27 earnings, with revenue from operations growing 20% YoY to Rs. 946 crores, EBITDA growing 59% YoY to Rs. 205 crores, and PAT more than doubling to Rs. 79 crores. The company's balance sheet shows improvement, with net debt decreasing to Rs. 86 crores and net debt to EBITDA ratio improving to 0.1x.

Viyash Scientific Ltd

Viyash Scientific Ltd has made available the audio recording of its earnings call for the unaudited financial results (consolidated and standalone) for the quarter ended June 30, 2026, on its website.

Viyash Scientific Ltd

Viyash Scientific Ltd has published the unaudited financial results for the quarter ended June 30, 2026, in The Financial Express and Nava Telangana newspapers, as per Regulation 30 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced its Q1 FY 2026-2027 unaudited financial results, showing a 19.5% YoY revenue growth and 21.6% EBITDA margin. The company has also reported a net debt of ₹861 Mn, a decrease of 19.5% from ₹1,661 Mn in Q4 FY26.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the voting results and scrutinizer report for its 41st Annual General Meeting (AGM). All resolutions were passed with requisite majority by remote e-voting and e-voting at the AGM. The company has also provided the voting results for the adoption of audited financial statements and the re-appointment of a director.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the voting results and scrutinizer report for its 41st Annual General Meeting. All resolutions were passed with the required majority. The company has also disclosed the voting results for two resolutions, including the adoption of audited financial statements and the re-appointment of a director.

Viyash Scientific Ltd

Viyash Scientific Ltd held its 41st AGM on August 11, 2026, through video conferencing. The meeting was attended by the required quorum, and the proceedings were conducted smoothly. The Company Secretary, Yoshita Vora, welcomed the members and confirmed the availability of statutory registers and documents for electronic inspection. Dr. Kamal Sharma, the Chairman, conducted the further proceedings and addressed the members on the Company's performance for the year. Dr. Haribabu Bodepudi, the Managing Director & Group CEO, provided a detailed performance overview for the year, key developments, and strategic focus.

Viyash Scientific Ltd

Viyash Scientific Ltd announces Q1 FY 2026-27 unaudited standalone and consolidated financial results, with revenues up 19.5%, EBITDA up 59.2%, and PAT up 114.9%. The company will conduct an earnings call on August 12, 2026.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the allotment of 10,30,775 equity shares under the Viyash Scientific Limited Employee Stock Option Scheme, 2026, at an exercise price of Rs. 101/- per equity share. The company has also approved the incorporation of a wholly owned subsidiary in Vietnam and investment therein, and subscription of equity shares in Alivira Animal Health Limited through a rights issue.

Viyash Scientific Ltd

Viyash Scientific Ltd's board meeting outcome: approved unaudited financial results, employee stock option scheme, incorporation of a wholly-owned subsidiary in Vietnam, and subscription of equity shares in the subsidiary through a rights issue.

Viyash Scientific Ltd

Viyash Scientific Ltd announced unaudited financial results for Q1 FY 2026-2027, with the Board approving the results along with Independent Auditor's Limited Review Report. The company also approved the allotment of equity shares to employees under the Viyash Scientific Limited Employee Stock Option Scheme, 2026, and the incorporation of a wholly owned subsidiary in Vietnam. Additionally, the Board approved the subscription of equity shares in Alivira Animal Health Limited, a wholly owned subsidiary, through Rights Issue.

Viyash Scientific Ltd

Viyash Scientific Ltd has scheduled a conference call on August 12, 2026, to discuss its Q1FY27 earnings/financial results.

Viyash Scientific Ltd

Viyash Scientific Ltd has scheduled a Board Meeting on August 11, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for Q1 FY 2026-27.

Viyash Scientific Ltd

Viyash Scientific Ltd has approved the allotment of 20,01,336 equity shares under the Employee Stock Option Plan 2020 at an exercise price of Rs. 86 per share. The issued and paid-up equity share capital will increase from Rs. 87,37,50,954 to Rs. 87,77,53,626.

Viyash Scientific Ltd

Viyash Scientific Ltd has executed a Sale and Purchase Agreement with the shareholders of BioForLife Italia S.r.l. for the acquisition of 100% of its issued and outstanding share capital for approximately EUR 16.976 million, subject to adjustment for the net financial position.